BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16643608)

  • 1. Urinary macromolecules and renal tubular cell protection from oxalate injury: comparison of normal subjects and recurrent stone formers.
    Tsujihata M; Tsujikawa K; Tei N; Yoshimura K; Okuyama A
    Int J Urol; 2006 Mar; 13(3):197-201. PubMed ID: 16643608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism underlying the low prevalence of pediatric calcium oxalate urolithiasis.
    Momohara C; Tsujihata M; Yoshioka I; Tsujimura A; Nonomura N; Okuyama A
    J Urol; 2009 Sep; 182(3):1201-9. PubMed ID: 19625038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary macromolecular substances as natural inhibitors of calcium oxalate crystal aggregation.
    Koide T; Takemoto M; Itatani H; Takaha M; Sonoda T
    Invest Urol; 1981 Mar; 18(5):382-6. PubMed ID: 6162821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
    Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
    J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of urinary organic macromolecules on crystallization of calcium oxalate: enhancement of nucleation.
    Drach GW; Thorson S; Randolph A
    Trans Am Assoc Genitourin Surg; 1979; 71():62-6. PubMed ID: 161827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystalline aggregation in vitro: interaction between urinary macromolecules and the micromolecular environment.
    Guerra A; Meschi T; Schianchi T; Allegri F; Novarini A; Borghi L
    Acta Biomed; 2002; 73(1-2):11-26. PubMed ID: 12233273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS; Hruska KA; Chandhoke PS
    J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers.
    Borghi L; Guerra A; Meschi T; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Mar; 55(3):1041-50. PubMed ID: 10027942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibronectin as a potent inhibitor of calcium oxalate urolithiasis.
    Tsujihata M; Miyake O; Yoshimura K; Kakimoto KI; Takahara S; Okuyama A
    J Urol; 2000 Nov; 164(5):1718-23. PubMed ID: 11025758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fibronectin content in urinary macromolecules between normal subjects and recurrent stone formers.
    Tsujihata M; Miyake O; Yoshimura K; Kakimoto K; Takahara S; Okuyama A
    Eur Urol; 2001 Oct; 40(4):458-62. PubMed ID: 11713403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diurnal variation in plasma oxalate concentration and oxalate clearance in calcium oxalate stone formers with special reference to the effect of oxalate loading].
    Kinoshita N
    Hinyokika Kiyo; 1987 Sep; 33(9):1331-41. PubMed ID: 3434488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas.
    Laube N; Hergarten S; Hoppe B; Schmidt M; Hesse A
    J Urol; 2004 Jul; 172(1):355-9. PubMed ID: 15201810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyanionic inhibitors of calcium oxalate crystal agglomeration in urine.
    Scurr DS; Latif AB; Sergeant V; Robertson WG
    Proc Eur Dial Transplant Assoc; 1983; 20():440-4. PubMed ID: 6197713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urinary calcium oxalate supersaturation beyond nephrolithiasis. Relationship with tubulointerstitial damage].
    Toblli JE; Angerosa M; Stella I; Ferder L; Inserra F
    Medicina (B Aires); 2003; 63(2):97-104. PubMed ID: 12793076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uric acid: an abettor or protector in calcium oxalate urolithiasis? Biochemical study in stone formers.
    Srinivasan S; Kalaiselvi P; Sakthivel R; Pragasam V; Muthu V; Varalakshmi P
    Clin Chim Acta; 2005 Mar; 353(1-2):45-51. PubMed ID: 15698589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations on calcium oxalate stone formers.
    el-Sharabasy MM
    Br J Urol; 1992 Nov; 70(5):474-7. PubMed ID: 1361403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of spontaneous crystalluria in patients with calcium oxalate calculi].
    Nguyen HV; Daudon M; Réveillaud RJ; Jungers P
    Nephrologie; 1987; 8(2):65-9. PubMed ID: 3614507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
    Hassani MA; Hennequin C; Lacour B; Daudon M
    Prog Urol; 2005 Sep; 15(4):650-5. PubMed ID: 16459680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.